Estimating endogenous dopamine levels at D 2 and D 3 receptors in humans using the agonist radiotracer 11 C-(+)-PHNO

Neuropsychopharmacology

Volumn 39, Issue 12, 2014, Pages 2769-2776

  Caravaggio, Fernando ^a,b   Nakajima, Shinichiro ^a,c   Borlido, Carol ^a   Remington, Gary ^a,b,c   Gerretsen, Philip ^a,b,c   Wilson, Alan ^a,b,c   Houle, Sylvain ^a,c   Menon, Mahesh ^a,c   Mamo, David ^a,c   Graff Guerrero, Ariel ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HOMOVANILLIC ACID; METIROSINE; NAXAGOLIDE; OXAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AFFECT; AGONISTS; BLOOD; BRAIN; DIAGNOSTIC USE; DRUG EFFECTS; FEMALE; HUMAN; MALE; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING;

ADULT; AFFECT; ALPHA-METHYLTYROSINE; BRAIN; DOPAMINE; DOPAMINE AGENTS; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 84936764958     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.125     Document Type: Article

References (50)

1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109.
2. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M (2009). Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65:1091-1093.
3. Adam R, Leff A, Sinha N, Turner C, Bays P, Draganski B et al (2013). Dopamine reverses reward insensitivity in apathy following globus pallidus lesions. Cortex 49:1292-1303.
4. Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979). Postmortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J Neural Transm 45:81-105.
5. Banerjee A, Prante O (2012). Subtype-selective dopamine receptor radioligands for PET imaging: current status and recent developments. Curr Med Chem 19:3957-3966.
6. Bloemen OJ, de Koning MB, Gleich T, Meijer J, de Haan L, Linszen DH et al (2013). Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at ultra high risk for psychosis. Eur Neuropsychopharmacol 23:126-132.
7. Cumming P (2011). Absolute abundances and affinity states of dopamine receptors in mammalian brain: a review. Synapse 65:892-909.
8. Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U et al (2002). The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann N Y Acad Sci 965:440-450.
9. Engelman K, Jequier E, Udenfriend S, Sjoerdsma A (1968). Metabolism of alpha-methyltyrosine in man: relationship to its potency as an inhibitor of catecholamine biosynthesis. J Clin Invest 47:568-576.
10. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR et al (1994). Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther 268:417-426.
11. Galineau L, Wilson AA, Garcia A, Houle S, Kapur S, Ginovart N (2006). In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. Synapse 60:172-183.
12. Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T et al (2012). Affinity and selectivity of [(1) (1) C]-(+) - PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66:489-500.
13. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P et al (2006). Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97:1089-1103.
14. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S et al (2007). Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27:857-871.
15. Gjedde A, Wong DF, Rosa-Neto P, Cumming P (2005). Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int Rev Neurobiol 63:1-20.
16. Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P et al (2010). Blockade of [11C] (+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 13:273-287.
17. Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P et al (2008). Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 29:400-410.
18. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279-287.
19. Gurevich EV, Joyce JN (1999). Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60-80.
20. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
21. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M et al (2010). Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231-239.
22. Kiss B, Horti F, Bobok A (2011). In vitro and in vivo comparison of [(3) H] (+)-PHNO and [(3) H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D (3) from D (2) receptor sites. Synapse 65:467-478.
23. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4(Pt 1):153-158.
24. Laruelle M (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451.
25. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL et al (1997). Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-174.
26. Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R et al (2009). Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D (2)/D (3) receptors following acute dopamine depletion. Am J Psychiatry 166:1170-1177.
27. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al (2001). Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D (2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057.
28. McCormick PN, Ginovart N, Wilson AA (2011). Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release. Mol Imaging Biol 13:737-746.
29. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E et al (2006). Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60:485-495.
30. Newberg AB, Moss AS, Monti DA, Alavi A (2011). Positron emission tomography in psychiatric disorders. Ann N Y Acad Sci 25:1749-6632.
31. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R et al (2009). In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63:782-793.
32. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M et al (2010). Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-399.
33. Searle GE, Beaver JD, Tziortzi A, Comley RA, Bani M, Ghibellini G et al (2013). Mathematical modelling of [(1) (1) C]-(+)-PHNO human competition studies. Neuroimage 68:119-132.
34. Seeman P (2013). Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol 23:999-1009.
35. Seeman P, Ulpian C, Larsen RD, Anderson PS (1993). Dopamine receptors labelled by PHNO. Synapse 14:254-262.
36. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S et al (2012). Within-subject comparison of [(11) C]-(+)-PHNO and [(11) C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 32:127-136.
37. Singh A, Mahgoub N, Klimstra S (2011). Apathy associated with a unilateral globus pallidus lesion: a case report. Int J Geriatr Psychiatry 26:765-766.
38. Studholme C, Hill DL, Hawkes DJ (1997). Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 24:25-35.
39. Tatsch K, Poepperl G (2012). Quantitative approaches to dopaminergic brain imaging. Q J Nucl Med Mol Imaging 56:27-38.
40. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M et al (2011). Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54:264-277.
41. Udenfriend S, Zaltzman-Nirenberg P, Nagatsu T (1965). Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol 14:837-845.
42. van Wieringen JP, Booij J, Shalgunov V, Elsinga P, Michel MC (2013). Agonist high- and low-affinity states of dopamine D (2) receptors: methods of detection and clinical implications. Naunyn Schmiedebergs Arch Pharmacol 386:135-154.
43. Verhoeff NP, Christensen BK, Hussey D, Lee M, Papatheodorou G, Kopala L et al (2003). Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol Biochem Behav 74:425-432.
44. Verhoeff NP, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA et al (2002). Dopamine depletion results in increased neostriatal D (2), but not D (1), receptor binding in humans. Mol Psychiatry 7:322-328.
45. Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Psych C et al (2001). A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 25:213-223.
46. Versteeg DH, Van Der Gugten J, De Jong W, Palkovits M (1976). Regional concentrations of noradrenaline and dopamine in rat brain. Brain Res 113:563-574.
47. Vijayaraghavan L, Vaidya JG, Humphreys CT, Beglinger LJ, Paradiso S (2008). Emotional and motivational changes after bilateral lesions of the globus pallidus. Neuropsychology 22:412-418.
48. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S et al (2008). First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 33:279-289.
49. Wilson AA, Garcia A, Jin L, Houle S (2000). Radiotracer synthesis from [(11) C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 27:529-532.
50. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D et al (2005). Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3, 4, 4a, 5, 6, 10b-hexahydro-2H-naphtho[1, 2-b][1, 4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153-4160.